Fig. 3
PK/PD and tumor targeting of F68-FDOX. a The pharmacokinetics (PK) profile of DOX, FRRG-DOX and F68-FDOX in mice. b The area under the curves (AUC), clearance (CL), volume of distribution (Vd) and half-life (t1/2) of DOX, FRRG-DOX and F68-FDOX in mice. c NIRF images of HT29 tumor-bearing mice after 9 h treatment with DOX, FRRG-DOX and F68-FDOX. d The ex vivo imaging of major organs and tumor tissues of HT29 tumor-bearing mice after 9 h treatment with DOX, FRRG-DOX and F68-FDOX. e The pharmacodynamics (PD) of DOX, FRRG-DOX and F68-FDOX in HT29 tumor-bearing mice after 9 h treatment. Significance was determined by Tukey−Kramer post-hoc test